Enliven Therapeutics
ELVN
ELVN
134 hedge funds and large institutions have $1.22B invested in Enliven Therapeutics in 2025 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 59 increasing their positions, 32 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
20.85% less ownership
Funds ownership: 121.12% → 100.28% (-21%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.4M
Holders
134
Holding in Top 10
6
Calls
–
Puts
$1.4M
Top Buyers
| 1 | +$18.6M | |
| 2 | +$11.3M | |
| 3 | +$9.92M | |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
+$8.81M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$7M |
Top Sellers
| 1 | -$17M | |
| 2 | -$16.4M | |
| 3 | -$16.4M | |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$9.99M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.82M |
